Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors

Area of Science:

• Oncology
• Endocrinology
• Medical Oncology

Background:

• Metastatic pancreatic neuroendocrine tumors (panNETs) have seen significant progress in systemic treatments.
• Optimal sequencing of these therapies for panNETs remains an area of clinical uncertainty.

Purpose of the Study:

• To review the classification of panNETs.
• To discuss current systemic treatment options for panNETs.
• To explore therapeutic sequencing strategies and active areas of investigation.

Main Methods:

• Literature review of systemic treatments for panNETs.
• Analysis of current guidelines and clinical trial data.
• Discussion of treatment sequencing based on disease characteristics.

Main Results:

• First-line therapy for somatostatin receptor (SSTR)-avid, well-differentiated metastatic panNETs is typically somatostatin analogs (SSAs).
• Post-SSA progression offers options including targeted agents (everolimus, sunitinib), peptide receptor radionuclide therapy (PRRT), and chemotherapy.
• Chemotherapy is often favored for panNETs with high tumor burden or aggressive features.

Conclusions:

• Effective management of panNETs requires understanding treatment options and sequencing strategies.
• Continued research is crucial for advancing panNET therapy and improving patient outcomes.